In CV disease, clopidogrel reduces nonfatal MI and MACE vs. aspirin but not stroke or mortality

Area of Science:

• Cardiology
• Pharmacology
• Clinical Research

Background:

• Established cardiovascular disease (CVD) necessitates antiplatelet therapy.
• Aspirin and clopidogrel are commonly used antiplatelet agents.
• Comparative effectiveness of monotherapy with these agents requires clarification.

Purpose of the Study:

• To systematically review and meta-analyze randomized controlled trials comparing clopidogrel monotherapy with aspirin monotherapy.
• To evaluate the efficacy and safety of clopidogrel versus aspirin in patients with established CVD.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials.
• Inclusion criteria focused on patients with established CVD receiving either clopidogrel or aspirin monotherapy.
• Primary outcomes included major adverse cardiovascular events (MACE) and bleeding events.

Main Results:

• No statistically significant difference in the incidence of MACE between clopidogrel monotherapy and aspirin monotherapy.
• Similar rates of major bleeding events were observed between the two treatment groups.
• Subgroup analyses did not reveal significant differences in efficacy or safety.

Conclusions:

• Clopidogrel monotherapy does not offer superior protection against major adverse cardiovascular events compared to aspirin monotherapy in patients with established CVD.
• Both antiplatelet monotherapies demonstrate comparable efficacy and safety profiles.
• Current evidence does not support a routine switch from aspirin to clopidogrel monotherapy for improved outcomes in this patient group.